Kiniksa Pharmaceuticals/$KNSA
1D1W1MYTD1Y5YMAX
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
- Ticker
- $KNSA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 366
- Headquarters
- London, United Kingdom
- Website
- www.kiniksa.com
KNSA Metrics
BasicAdvanced
$6B
77.50
$0.99
0.07
-
Price and volume
Market cap
$6B
Beta
0.07
52-week high
$82.94
52-week low
$32.89
Average daily volume
681K
Financial strength
Current ratio
3.904
Quick ratio
3.208
Long term debt to equity
0.747
Total debt to equity
1.36
Profitability
EBITDA (TTM)
102.041
Gross margin (TTM)
54.50%
Net profit margin (TTM)
9.59%
Operating margin (TTM)
11.92%
Effective tax rate (TTM)
29.40%
Revenue per employee (TTM)
$2,300,000
Management effectiveness
Return on assets (TTM)
8.05%
Return on equity (TTM)
14.04%
Valuation
Price to earnings (TTM)
77.502
Price to revenue (TTM)
6.956
Price to book
9.15
Price to tangible book (TTM)
9.36
Price to free cash flow (TTM)
31.989
Free cash flow yield (TTM)
3.13%
Free cash flow per share (TTM)
2.399
Growth
Revenue change (TTM)
58.85%
Earnings per share change (TTM)
1,399.63%
3-year revenue growth (CAGR)
44.13%
3-year earnings per share growth (CAGR)
-32.56%
What the Analysts think about KNSA
Analyst ratings (Buy, Hold, Sell) for Kiniksa Pharmaceuticals stock.
KNSA Financial Performance
Revenues and expenses
KNSA Earnings Performance
Company profitability
KNSA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.